Bliss GVS Pharma Stock Screener | Share Price & Fundamental Analysis
BLISSGVS
Pharmaceuticals
Screen Bliss GVS Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹160.42
▼
-2.40 (-1.47%)
Share Price BSE
₹160.55
▼
-2.30 (-1.41%)
Market Cap
₹1,713.87 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
1.53
EPS (TTM)
₹8.02
Dividend Yield
0.30%
Debt to Equity
0.09
52W High
₹183.17
52W Low
₹111.84
Operating Margin
11.00%
Profit Margin
8.10%
Revenue (TTM)
₹210.00
EBITDA
₹33.00
Net Income
₹17.00
Total Assets
₹1,301.00
Total Equity
₹1,092.00
Bliss GVS Pharma Share Price History - Stock Screener Chart
Screen BLISSGVS historical share price movements with interactive charts. Analyze price trends and patterns.
Bliss GVS Pharma Company Profile - Fundamental Screener
Screen Bliss GVS Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BLISSGVS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE416D01022
Bliss GVS Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen BLISSGVS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,301 | 1,212 | 1,157 | 1,109 | 1,077 | 1,027 | 905 | 860 | 1,023 | 762 |
| Current Assets | 827 | 811 | 697 | 777 | 765 | 770 | 694 | 690 | 566 | 471 |
| Fixed Assets | 406 | 370 | 379 | 282 | 234 | 242 | 146 | 143 | 305 | 225 |
| Liabilities | ||||||||||
| Total Liabilities | 1,301 | 1,212 | 1,157 | 1,109 | 1,077 | 1,027 | 905 | 860 | 1,023 | 762 |
| Current Liabilities | 37 | 51 | 46 | 29 | 45 | 46 | 38 | 13 | 33 | 50 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,092 | 1,003 | 917 | 847 | 828 | 750 | 660 | 548 | 553 | 446 |
| Share Capital | 11 | 11 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves & Surplus | 1,040 | 957 | 874 | 808 | 798 | 725 | 636 | 526 | 476 | 402 |
Screen BLISSGVS income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 210 | 243 | 265 | 204 | 188 | 223 | 226 | 188 | 165 | 225 | 206 | 179 | 196 | 175 | 211 |
| Expenses | 177 | 166 | 213 | 199 | 149 | 176 | 181 | 179 | 135 | 158 | 157 | 147 | 150 | 148 | 158 |
| EBITDA | 33 | 77 | 52 | 5 | 39 | 47 | 45 | 9 | 29 | 67 | 49 | 32 | 46 | 27 | 53 |
| Operating Profit % | 11.00% | 20.00% | 13.00% | 0.00% | 19.00% | 19.00% | 14.00% | 3.00% | 15.00% | 26.00% | 22.00% | 12.00% | 21.00% | 14.00% | 23.00% |
| Depreciation | 8 | 8 | 8 | 7 | 7 | 7 | 8 | 5 | 6 | 6 | 7 | 4 | 5 | 5 | 5 |
| Interest | 2 | 6 | 3 | 2 | 2 | 4 | 1 | 5 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Profit Before Tax | 23 | 63 | 41 | -4 | 30 | 36 | 36 | -1 | 22 | 59 | 40 | 27 | 39 | 20 | 47 |
| Tax | 7 | 19 | 12 | 1 | 8 | 10 | 11 | -4 | 7 | 16 | 11 | 3 | 12 | 4 | 18 |
| Net Profit | 17 | 44 | 29 | -5 | 22 | 26 | 26 | 4 | 14 | 43 | 29 | 24 | 28 | 16 | 30 |
| EPS | 1.47 | 4.08 | 2.58 | -0.88 | 1.97 | 2.31 | 2.27 | 0.34 | 1.41 | 4.06 | 2.64 | 1.90 | 2.48 | 1.33 | 2.68 |
Bliss GVS Pharma Cash Flow Screener - Liquidity Fundamentals
Screen BLISSGVS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 106 | 103 | 34 | 136 | 64 | 47 | 40 | 18 | 290 | 113 |
| Investing Activities | -75 | -83 | -6 | -103 | -45 | -40 | -79 | 48 | -249 | -50 |
| Financing Activities | -30 | -21 | -25 | -24 | -21 | -6 | 17 | -76 | -10 | -40 |
| Net Cash Flow | 0 | -1 | 3 | 9 | -2 | 0 | -22 | -11 | 30 | 23 |
Screen BLISSGVS shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 35.39% | 35.44% | 35.29% | 35.10% | 34.82% | 34.90% | 34.97% | 34.97% |
| FII Holding | 13.27% | 12.65% | 13.18% | 13.51% | 12.13% | 13.25% | 14.73% | 0.00% |
| DII Holding | 5.98% | 6.54% | 6.55% | 6.55% | 6.57% | 6.58% | 6.59% | 6.59% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 32.85% | 32.79% | 32.63% | 32.93% | 34.57% | 32.84% | 31.71% | 30.78% |
| Other Holding | 12.51% | 12.58% | 12.34% | 11.91% | 11.92% | 12.43% | 12.00% | 27.66% |
| Shareholder Count | 44,461 | 46,707 | 49,517 | 49,558 | 52,937 | 44,737 | 45,157 | 40,758 |
Bliss GVS Pharma Dividend Screener - Share Yield Analysis
Screen BLISSGVS dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.50 | 0.31% |
| 2024-March | ₹0.50 | 0.42% |
| 2023-March | ₹0.50 | 0.44% |
| 2022-March | ₹0.50 | 0.71% |
| 2021-March | ₹0.50 | 0.65% |
| 2020-March | ₹0.50 | 0.51% |
| 2019-March | ₹1.00 | 0.99% |
| 2018-March | ₹1.00 | 0.56% |
| 2017-March | ₹0.60 | 0.31% |
Bliss GVS Pharma Index Membership - Market Screener Classification
Screen BLISSGVS by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Bliss GVS Pharma Market Events Screener - Corporate Actions
Screen BLISSGVS market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 0.50 /share | -9.72% | ||
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | 1.19% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 63.78% |
| 2025-07-29 | 2025-07-29 | Quarterly Result Announcement | NA | -4.19% |
| 2025-07-24 | 2025-07-24 | Dividend | ₹ 0.50 /share | 40.29% |
| 2025-05-12 | 2025-05-12 | Quarterly Result Announcement | NA | -5.06% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -13.24% |
| 2024-10-24 | 2024-10-24 | Quarterly Result Announcement | NA | -0.92% |
| 2024-07-25 | 2024-07-25 | Annual General Meeting | NA | -1.94% |
| 2024-07-18 | 2024-07-19 | Dividend | ₹ 0.50 /share | -9.96% |
| 2023-07-19 | 2023-07-19 | Annual General Meeting | NA | 21.42% |
| 2023-07-12 | 2023-07-13 | Dividend | ₹ 0.50 /share | 0.97% |
| 2022-06-28 | 2022-06-28 | Annual General Meeting | NA | -6.59% |
| 2022-06-20 | 2022-06-21 | Dividend | ₹ 0.50 /share | -10.26% |
Bliss GVS Pharma Competitors Screener - Peer Comparison
Screen BLISSGVS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Bliss GVS Pharma Company Announcements - News Screener
Screen BLISSGVS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-01-04 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | View |
| 2026-01-04 | Closure of Trading Window | View |
| 2025-12-28 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-28 | Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday December 23 2025 | View |
| 2025-12-09 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-11-25 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-11-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-06 | Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019 | View |
| 2025-11-06 | Details Of Kmps For Reporting Of Disclosure Of Material Events To Stock Exchanges | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-06 | Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Yearly Ended September 30 2025 | View |
| 2025-11-06 | Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday November 06 2025 | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-10-29 | Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-10-10 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-10-06 | Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-10-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |